3-溴-8-氯咪唑并[1,2-a]吡嗪 | 143591-61-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 中文名称: 3-溴-8-氯咪唑并[1,2-a]吡嗪
• 中文别名: 3-溴-8-氯咪唑并[1,2-A]吡嗪
• 英文名称: 3-bromo-8-chloroimidazo[1,2-a]pyrazine
• CAS: 143591-61-1
• 化学式: C₆H₃BrClN₃
• mdl: MFCD09909653
• 分子量: 232.467
• InChiKey: MCEGPQSPRNOFMG-UHFFFAOYSA-N

物化性质

• 密度：
  2.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromo-8-chloroimidazo[1,2-a]pyrazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-8-chloroimidazo[1,2-a]pyrazine
CAS number: 143591-61-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3BrClN3
Molecular weight: 232.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-8-氯咪唑并[1,2-a]吡嗪 在 Ammonium hydroxide 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 3-溴咪唑并[1,2-a]吡嗪-8-胺
  参考文献：
  名称：

  咪唑并[1,2- a ]喹喔啉类药物治疗黑色素瘤的原始作用机制

  摘要：

  黑色素细胞的恶性转化每年导致数千人死亡，这使黑色素瘤成为重要的公共卫生问题。黑色素瘤是最具有侵略性的皮肤癌，在过去的几十年中，其发病率定期增加。我们在这里描述了基于1-（3,4-二羟基苯基）咪唑并[1,2- a ]喹喔啉结构的新化合物的制备。筛选喹喔啉部分的不同位置以引入新的取代基，以研究其对生物活性的影响。还考虑了几个烷基氨基或烷氧基取代我们第一代咪喹啉的甲胺。咪唑[1,2- a]吡嗪衍生物也被设计为潜在的最小结构。对A375黑色素瘤细胞的研究显示出有趣的体外低纳摩尔细胞毒活性。其中，9d（EAPB02303）特别引人注目，因为它的功效比维拉非尼（用于BRAF突变黑素瘤的参考临床疗法）高20倍。与第一代产品相反，EAPB02303不会抑制微管蛋白的聚合，这一点已通过体外试验和分子模型研究证实。转录组分析突出显示的EAPB02303的作用机制与一组12种著名的抗癌药物明显不同。体内 EAPB02303

  DOI：

  10.1016/j.ejmech.2020.113031
• 作为产物：
  描述：

  8-chloroimidazo[1,2-a]pyrazine hydrobromide 在 溴 作用下， 以 溶剂黄146 为溶剂， 反应 73.67h， 以91%的产率得到3-溴-8-氯咪唑并[1,2-a]吡嗪
  参考文献：
  名称：

  Methods for inhibiting protein kinases

  摘要：

  本发明提供了利用咪唑并[1,2-a]吡嗪化合物抑制来自AKT、检查点激酶、枢纽激酶、Pim-1激酶和酪氨酸激酶的蛋白激酶的方法，以及利用这些化合物治疗、预防、抑制或改善与蛋白激酶相关的一种或多种疾病的方法。

  公开号：

  US20070105864A1

文献信息

• [EN] METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR LA KINASE RAF
  申请人：ARIAD PHARMA INC

  公开号：WO2013162727A1

  公开（公告）日：2013-10-31

  The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.

  该发明揭示了通过给予化合物Formula 1或其药学上可接受的盐、溶剂或水合物来治疗或预防由RAF激酶介导的疾病或症状的方法和组合物，其中变量如本文所定义。
• [EN] FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'HÉTÉROARYLES FUSIONNÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS DES ORÉXINES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016101119A1

  公开（公告）日：2016-06-30

  Fused heteroaryl derivative compounds which are antagonists of orexin receptors are provided. The compounds can be used in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. Also provided is a composition which comprises the compound can be use to prevent or treat such diseases in which orexin receptors are involved.

  提供了与异杂环衍生物化合物，这些化合物是促进睡眠的受体拮抗剂。这些化合物可用于潜在治疗或预防涉及促进睡眠的受体的神经和精神疾病。还提供了一种包含该化合物的组合物，可用于预防或治疗涉及促进睡眠的受体的这类疾病。
• Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities
  作者：Yichang Ren、Yuxi Wang、Gang Li、Zherong Zhang、Lingling Ma、Binbin Cheng、Jianjun Chen

  DOI：10.1021/acs.jmedchem.0c01837

  日期：2021.4.22

  Novel indazole and benzimidazole analogues were designed and synthesized as tubulin inhibitors with potent antiproliferative activities. Among them, compound 12b exhibited the strongest inhibitory effects on the growth of cancer cells with an average IC50 value of 50 nM, slightly better than colchicine. 12b exhibited nearly equal potency against both, a paclitaxel-resistant cancer cell line (A2780/T

  设计并合成了新型吲唑和苯并咪唑类似物，作为具有有效抗增殖活性的微管蛋白抑制剂。其中，化合物12b对癌细胞的生长表现出最强的抑制作用，平均IC 50值为50 nM，略高于秋水仙碱。12b对紫杉醇抗性癌细胞系（A2780 / T，IC 50 = 9.7 nM）和相应的亲代细胞系（A2780S，IC 50 = 6.2 nM）表现出几乎相等的效力，因此在体外有效克服了对紫杉醇的抗性。12b的晶体结构通过X射线晶体学分析，将与微管蛋白复合的化合物拆分至2.45Å分辨率，并确认其直接结合至秋水仙碱位点。此外，12b在黑素瘤肿瘤模型中显示出显着的体内抗肿瘤功效，肿瘤生长抑制率分别为78.70％（15 mg / kg）和84.32％（30 mg / kg）。总的来说，这项工作表明12b是一种有前途的铅化合物，作为潜在的抗癌剂值得进一步研究。
• [EN] IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRAZINE ET LEUR UTILISATION POUR LA PRÉVENTION OU LE TRAITEMENT DE TROUBLES ET MALADIES NEUROLOGIQUES, PSYCHIATRIQUES ET MÉTABOLIQUES.
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011110545A1

  公开（公告）日：2011-09-15

  The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

  本发明涉及新型咪唑并[1,2-a]吡嗪衍生物，它们是磷酸二酯酶10（PDE10）的抑制剂，并且对涉及PDE10酶的神经、精神和代谢性疾病的治疗或预防具有用处。该发明还涉及包含这类化合物的药物组合物，用于制备这类化合物和组合物的方法，以及利用这类化合物或药物组合物预防或治疗神经、精神和代谢性疾病和疾病。
• IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES
  申请人：Bartolomé-Nebreda José Manuel

  公开号：US20120329792A1

  公开（公告）日：2012-12-27

  The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

  本发明涉及新型咪唑并[1,2-a]吡嗪衍生物，其为磷酸二酯酶10（PDE10）的抑制剂，并且适用于治疗或预防涉及PDE10酶的神经、精神和代谢性疾病。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物或药物组合物预防或治疗神经、精神和代谢性疾病和疾病。